David Schweikert: “Last week, I got behind this microphone, and we were actually trying to show something that was a bit optimistic. But…”

“Last week, I got behind this microphone, and we were actually trying to show something that was a bit optimistic. But like everyone else on our side, the frustration we are going through on so many of the Democrat policies that I don't think were meant to be mean-spirited or so dystopian in the damage they cause, particularly to the working poor, which is one of my fixations-- sometimes, the economics is the economics, sometimes virtue signaling over the unintended consequences. I want to go over something and try to explain why I think this is such a big deal for both those on the left and those of us on the right. There is actually a window of optimism, but it is going to take a policy pivot. Last week, I got up here and talked about--remember, I gave a couple of presentations last December, a major success in curing type 1 diabetes. Now, it was really only one use case where they were able to take T cells and convert them into insulin-producing cells. In that particular one, the individual would need some immunosuppressants because of the body's reaction to it. Now, we have an organization that is doing some of the same technology with T cells, turning them into insulin-producing cells but with CRISPR as a partner. They are doing a tiny tweak. The model says the body won't recognize it as a foreign cell, and you won't need immunosuppressant drugs for the rest of your life. Conceptually, why is this such a big, big, big deal to have a cure for type 1?…”